Join
Live feed
·
PRReleasevia Quantisnow
Fate Therapeutics Inc. logo

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

ByQuantisnow·Wall Street's wire, on your screen.
FATE· Fate Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FATE (Fate Therapeutics Inc.) and more on Quantisnow.